兽医内分泌学市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球兽医内分泌市场规模为 4.145 亿美元，预计到 2034 年将以 6.5% 的复合年增长率增长至 7.703 亿美元。随着动物（尤其是宠物）中库欣氏症候群、糖尿病和阿狄森氏症等荷尔蒙失调疾病的发生率不断上升，该市场发展势头强劲。宠物拥有率的上升，加上人类与动物之间联繫的加深，正在推动全球对宠物医疗保健的需求。即时诊断技术的出现扩大了先进疗法的可及性，加上人们对慢性动物疾病认知的不断提高，内分泌学已成为兽医学中最具活力的领域之一。治疗方法的不断改进以及伴侣动物和家畜对长期疾病管理的需求，正在进一步塑造市场。

随着政府和私营部门利益相关者致力于加强动物保健体系，亚太和拉丁美洲新兴市场对兽医服务和基础设施的快速投资也正在促进产业扩张。兽医诊所、诊断实验室和远距医疗能力的资金投入增加，正在改善包括内分泌科在内的专科护理的可近性。伴侣动物饲养量的增加，加上宠物预防和慢性疾病管理的趋势，正在加速对先进荷尔蒙疗法和诊断工具的需求。本地生产设施、兽医专业人员培训以及与跨国製药公司的合作，也为这些高潜力地区的长期成长和市场渗透奠定了坚实的基础。

2024年，兽医内分泌学市场中的药物治疗细分市场占76.5%的份额。该细分市场的领先地位源于其价格实惠、长期使用以及在治疗常见动物内分泌疾病方面疗效稳定等特点，使其被广泛采用。甲状腺功能减退症、糖尿病和肾上腺功能障碍等慢性疾病通常需要持续的医疗干预。这些治疗中使用的药物受益于改进的药物配方，从而提高了治疗效果并提高了宠物主人的依从性。随着早期诊断变得越来越常规，尤其是在城市诊所，基于药物的治疗方案仍然是大多数地区的主要治疗方案。

在内分泌疾病类型中，糖尿病细分市场到2034年的复合年增长率将达到6.4%。一个关键因素是宠物肥胖率的上升，尤其是老年猫狗，这与过度餵食和缺乏运动有关。这催生了对先进糖尿病管理产品和护理方案的持续需求。科技显着改善了疾病管理，长效胰岛素製剂和自动血糖监测设备等工具如今能够更精确、更持续地控制动物的糖尿病症状。这些创新提升了实务工作者的信心，也增强了宠物主人参与治疗的意愿。

2024年，美国兽医内分泌市场产值达1.551亿美元。美国在该市场的领先地位主要归功于其早期采用新技术，例如动态血糖监测（CGM）和针对激素紊乱的远距医疗服务，以及专注于内分泌学的兽医专家的广泛存在。犬甲状腺功能减退症和猫糖尿病病例的增加，持续推高了对诊断和标靶治疗的需求。此外，人们对宠物肥胖相关疾病的认识不断提高，以及完善的製药和监管环境，有助于美国保持市场主导地位。拥有大量产品组合和研发管线的公司正在加速兽药审批，并推出客製化治疗方案，以满足这些日益增长的需求。

引领兽医内分泌市场的主要参与者包括礼来动物保健、勃林格殷格翰、默克、德克製药、硕腾、MedPharm 动物保健、Med-Pharmex、维克、Kela Health、Vivaldis 动物保健和 Nextmune。这些公司在不断创新的同时，也加强了其全球分销和产品线。领先的兽医内分泌公司正积极拓展其产品线，投资长效製剂和先进的给药系统，以提高治疗顺从性。他们也透过策略伙伴关係和收购，增强在服务不足和高成长地区的影响力。各公司正专注于将诊断和治疗相结合，提供全面护理解决方案，尤其针对糖尿病等慢性内分泌疾病。该公司专注于兽医培训计画和宠物主人宣传活动，以提高早期诊断和治疗的采用率。远距兽医平台和行动诊断等数位工具正越来越多地用于改善医疗服务并简化护理流程。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 伴侣动物和牲畜内分泌失调的盛行率不断上升
    • 增加宠物拥有量和宠物人性化
    • 宠物肥胖发生率上升
    • 监管支持和增加药品审批
  • 产业陷阱与挑战
    • 治疗费用高且治疗时间长
    • 兽医内分泌专家有限
  • 市场机会
    • 伴侣动物数量增长和慢性疾病负担
    • 即时诊断和家庭诊断的进步
• 成长潜力分析
• 监管格局
• 技术格局
  • 当前的技术趋势
  • 新兴技术
• 定价分析
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
  • 全球的
  • 北美洲
  • 欧洲
  • 亚太地区
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 伙伴关係与协作
  • 新产品发布
  • 扩张计划

第五章：市场估计与预测：按治疗类型，2021 - 2034 年

• 主要趋势
• 药物治疗
  • 依药物类型
    • 胰岛素和抗糖尿病药物
    • 甲状腺激素替代疗法
    • 肾上腺激素调节剂
    • 生殖荷尔蒙
    • 其他药物类型
  • 依给药途径
    • 口服
    • 注射剂
    • 外用
    • 其他给药途径
• 非药物治疗

第六章：市场估计与预测：依疾病类型，2021 - 2034 年

• 主要趋势
• 糖尿病
• 甲状腺功能低下症
• 甲状腺功能亢进
• 库欣氏症候群
• 艾迪生病
• 生殖障碍
• 其他疾病类型

第七章：市场估计与预测：按动物类型，2021 - 2034 年

• 主要趋势
• 伴侣动物
  • 狗
  • 猫
  • 其他伴侣动物
• 牲畜
  • 牛
  • 绵羊和山羊
  • 其他牲畜

第八章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 兽医医院和诊所
• 零售兽药局
• 其他最终用途

第九章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Boehringer Ingelheim
• Dechra Pharmaceuticals
• Elanco Animal Health
• Kela Health
• Merck
• MedPharm Animal Health
• Med-Pharmex
• Nextmune
• Virbac
• Vivaldis Animal Health
• Zoetis

The Global Veterinary Endocrinology Market was valued at USD 414.5 million in 2024 and is estimated to grow at a CAGR of 6.5% to reach USD 770.3 million by 2034. This market is gaining momentum due to the increasing incidence of hormonal disorders like Cushing's syndrome, diabetes mellitus, and Addison's disease in animals, especially pets. Rising pet ownership rates, coupled with the growing human-animal bond, are driving global demand for pet healthcare. The availability of point-of-care diagnostics expanded access to advanced therapies, and growing awareness around chronic animal diseases has made endocrinology one of the more dynamic segments in veterinary medicine. Ongoing improvements in therapeutic delivery and the demand for long-term disease management across companion and livestock animals are further shaping the market.

Rapid investment in veterinary services and infrastructure in emerging markets across Asia-Pacific and Latin America is also reinforcing industry expansion, as governments and private stakeholders focus on strengthening animal healthcare systems. Increased funding for veterinary clinics, diagnostic laboratories, and telemedicine capabilities is improving access to specialized care, including endocrinology. The rise in companion animal ownership, coupled with a shift toward preventive and chronic disease management in pets, is accelerating demand for advanced hormonal therapies and diagnostic tools. Local production facilities, training of veterinary professionals, and collaborations with multinational pharmaceutical companies are also creating a strong foundation for long-term growth and market penetration in these high-potential regions.

The Pharmacological treatment segment in the veterinary endocrinology market held a 76.5% share in 2024. This segment's leadership stems from widespread adoption due to affordability, long-term use, and consistent outcomes in treating common endocrine disorders in animals. Chronic conditions such as hypothyroidism, diabetes, and adrenal dysfunction typically require sustained medical intervention. Medications used in these treatments benefit from enhanced drug formulations, allowing for improved therapeutic efficacy and better compliance from pet owners. With early diagnosis becoming more routine, especially in urban clinics, drug-based protocols remain the primary line of care across most regions.

Among endocrine disease types, the diabetes mellitus segment will grow at a CAGR of 6.4% through 2034. A key contributing factor is rising pet obesity-particularly among aging cats and dogs-linked to overfeeding and limited physical activity. This has created a continuous demand for advanced diabetes management products and care regimens. Technology has significantly improved disease management, as tools such as long-acting insulin formulations and automated glucose monitoring devices now enable more precise, consistent control of diabetic symptoms in animals. These innovations have elevated both practitioner confidence and owner willingness to engage in treatment.

United States Veterinary Endocrinology Market generated USD 155.1 million in 2024. The country's leadership in the market is largely attributed to early adoption of new technologies, such as CGMs and telehealth services for hormonal disorders, as well as the widespread presence of veterinary specialists focused on endocrinology. Rising cases of hypothyroidism in dogs and diabetes in cats continue to push up demand for diagnostics and targeted therapies. Additionally, growing awareness of obesity-related diseases in pets and a well-established pharmaceutical and regulatory environment help maintain U.S. dominance. Companies with large portfolios and R&D pipelines are accelerating veterinary drug approvals and launching tailored treatments to address these growing needs.

The major players leading the Veterinary Endocrinology Market include Elanco Animal Health, Boehringer Ingelheim, Merck, Dechra Pharmaceuticals, Zoetis, MedPharm Animal Health, Med-Pharmex, Virbac, Kela Health, Vivaldis Animal Health, and Nextmune. These companies continue to innovate while strengthening their global distribution and product lines. Leading veterinary endocrinology companies are actively expanding their product pipelines by investing in long-acting formulations and advanced delivery systems to improve treatment compliance. They are also enhancing their presence in underserved and high-growth regions through strategic partnerships and acquisitions. Companies are focusing on integrated care solutions by combining diagnostics and therapeutics, especially for chronic endocrine disorders like diabetes. Emphasis is placed on training programs for veterinarians and awareness campaigns for pet owners to increase early diagnosis and treatment adoption. Digital tools such as tele-vet platforms and mobile diagnostics are increasingly used to improve access and streamline care.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Treatment type trends
  • 2.2.3 Disease type trends
  • 2.2.4 Animal type trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of endocrine disorders in both companion and livestock animals
    • 3.2.1.2 Increasing pet ownership and humanization of pets
    • 3.2.1.3 Rising incidence of obesity in pets
    • 3.2.1.4 Regulatory support and increasing drug approvals
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment and long-term therapy
    • 3.2.2.2 Limited veterinary endocrinology specialists
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing companion animal population and chronic disease burden
    • 3.2.3.2 Advancement in point-of-care and at-home diagnostics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pricing analysis
• 3.7 Future market trends
• 3.8 GAP analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Pharmacological treatment
  • 5.2.1 By drug type
    • 5.2.1.1 Insulin and antidiabetics
    • 5.2.1.2 Thyroid hormone replacement
    • 5.2.1.3 Adrenal hormone modulators
    • 5.2.1.4 Reproductive hormones
    • 5.2.1.5 Other drug types
  • 5.2.2 By route of administration
    • 5.2.2.1 Oral
    • 5.2.2.2 Injectable
    • 5.2.2.3 Topical
    • 5.2.2.4 Other routes of administration
• 5.3 Non-pharmacological treatment

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Diabetes mellitus
• 6.3 Hypothyroidism
• 6.4 Hyperthyroidism
• 6.5 Cushing's syndrome
• 6.6 Addison's disease
• 6.7 Reproductive disorders
• 6.8 Other disease types

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Companion animals
  • 7.2.1 Dogs
  • 7.2.2 Cats
  • 7.2.3 Other companion animals
• 7.3 Livestock animals
  • 7.3.1 Cattle
  • 7.3.2 Sheep and goats
  • 7.3.3 Other livestock animals

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals and clinics
• 8.3 Retail veterinary pharmacies
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Boehringer Ingelheim
• 10.2 Dechra Pharmaceuticals
• 10.3 Elanco Animal Health
• 10.4 Kela Health
• 10.5 Merck
• 10.6 MedPharm Animal Health
• 10.7 Med-Pharmex
• 10.8 Nextmune
• 10.9 Virbac
• 10.10 Vivaldis Animal Health
• 10.11 Zoetis